Jyong Biotech (NASDAQ:MENS) Trading Down 4.7% - What's Next?

Key Points

• Jyong Biotech's shares have experienced a 4.7% decline, trading as low as $60.02 and showing a significant drop in volume to 18,298 shares compared to its average of 189,468 shares.
• Despite the recent drop, Wall Street Zen has upgraded the stock to a "hold" rating, indicating potential for growth.
• The company focuses on developing innovative plant-derived drugs primarily targeting urinary system diseases, with aspirations in the U.S., EU, and Asian markets.

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report)'s share price was down 4.7% during trading on Friday . The stock traded as low as $60.02 and last traded at $61.38. Approximately 18,298 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 189,468 shares. The stock had previously closed at $64.42.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised Jyong Biotech to a "hold" rating in a report on Monday, June 30th.

Jyong Biotech Stock Down 3.9%

The stock has a 50-day moving average of $33.37.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.